Xilio Therapeutics, (id:8370 XLO)
0.892 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 7:31:23 PM)
Exchange closed, opens in 13 hours 58 minutes
-1.98 USD (-1.98%)
-15.85 USD (-15.85%)
8.78 USD (8.78%)
-15.05 USD (-15.05%)
-20.36 USD (-20.36%)
-94.05 USD (-94.05%)
About Xilio Therapeutics,
Market Capitalization 43.85M
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
| Headquarters (address) |
828 Winter Street Waltham 02451 MA United States |
| Phone | 857 524 2466 |
| Website | https://xiliotx.com |
| Employees | 73 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | XLO |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.490 - 1.93 |
| Market Capitalization | 43.85M |
| P/E trailing | -0.321 |
| P/E forward | -1.72 |
| Price/Sale | 18.61 |
| Price/Book | 0.748 |
| Beta | -0.199 |
| EPS | -1.98 |
| EPS United States (ID:6, base:3402) | 24.22 |